Kidney Renal Papillary Cell Carcinoma: Correlation between gene mutation status and selected clinical features<BR>(primary solid tumor cohort)

Kidney Renal Papillary Cell Carcinoma: Correlation between gene mutation status and selected clinical features
(primary solid tumor cohort)

Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)

Overview

Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 7 genes and 8 clinical features across 99 patients, one significant finding detected with Q value < 0.25.

IL32 mutation correlated to 'Time to Death'.

Results

Overview of the results

Table 1. Get Full Table Overview of the association between mutation status of 7 genes and 8 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, one significant finding detected.


		Clinical Features	Time to Death	AGE	GENDER	KARNOFSKY PERFORMANCE SCORE	PATHOLOGY T	PATHOLOGY N	PATHOLOGICSPREAD(M)	TUMOR STAGE
	nMutated (%)	nWild-Type	logrank test	t-test	Fisher's exact test	t-test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test
IL32	4 (4%)	95	9.44e-15 (4.25e-13)	0.37 (1.00)	0.301 (1.00)		0.783 (1.00)		0.222 (1.00)	0.671 (1.00)
CDC27	4 (4%)	95	0.598 (1.00)	0.782 (1.00)	0.593 (1.00)		0.783 (1.00)		0.129 (1.00)	0.452 (1.00)
MET	7 (7%)	92	0.695 (1.00)	0.877 (1.00)	1 (1.00)		1 (1.00)		1 (1.00)	0.892 (1.00)
PCF11	7 (7%)	92	0.834 (1.00)	0.399 (1.00)	0.423 (1.00)		0.749 (1.00)	0.202 (1.00)	0.58 (1.00)	1 (1.00)
SFRS2IP	5 (5%)	94	0.226 (1.00)	0.121 (1.00)	0.657 (1.00)		0.107 (1.00)	1 (1.00)	0.0839 (1.00)	0.328 (1.00)
NF2	6 (6%)	93	0.598 (1.00)	0.139 (1.00)	1 (1.00)		0.301 (1.00)	0.0583 (1.00)	0.0252 (1.00)	0.0619 (1.00)
LGI4	4 (4%)	95	0.19 (1.00)	0.913 (1.00)	0.301 (1.00)		0.783 (1.00)		0.707 (1.00)	0.671 (1.00)

'IL32 MUTATION STATUS' versus 'Time to Death'

P value = 9.44e-15 (logrank test), Q value = 4.2e-13

Table S1. Gene #3: 'IL32 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	92	14	0.0 - 182.7 (14.4)
IL32 MUTATED	4	1	3.6 - 7.9 (4.8)
IL32 WILD-TYPE	88	13	0.0 - 182.7 (15.1)

Figure S1. Get High-res Image Gene #3: 'IL32 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

Methods & Data

Input

Mutation data file = KIRP-TP.mutsig.cluster.txt
Clinical data file = KIRP-TP.clin.merged.picked.txt
Number of patients = 99
Number of significantly mutated genes = 7
Number of selected clinical features = 8
Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References

[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)

[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)

[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)

[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)

Made with Nozzle